SNAP-GWAS: An integrated precision medicine platform to predict antibiotic treatment outcomes in SNAP (Phase 1)

• A large amount of variation exists within the genome of pathogenic Staphylococcus aureus that can be observed between regions or even individuals. These genetic differences can affect how the pathogen interacts with the host and administered treatments.
  ‍
• These genetic differences could affect the optimal treatment regimen for any one individual with a Staphylococcus aureus bloodstream infection.
  ‍
• This study aims to use a computational approach to compare the genomes of different strains of S. aureus pathogens to identify markers that can be used to steer clinicians' decisions to the best possible treatment option at a targeted, individual level.

• Phase 1: proof-of-concept study including 200 Australian methicillin-susceptible S. aureus (MSSA) isolates. Preliminary data from this study will be leveraged towards a larger grant